|Title:||Primed Human Bone Marrow Mesenchymal Stromal Cells as a Therapeutic Strategy for Klebsiella Pneumonia|
|Author(s):||CH Masterson D Byrnes H Gonzalez SD McCarthy DP O'Toole JG Laffey|
|Institution:||National University of Ireland, Galway|
|Poster:||Click to view poster|
|Category:||CF and Pulmonary Infections|
|Abstract:||Introduction: Bacterial infection remains the leading cause of ARDS development and death in critically ill patients. Klebsiella pneumoniae is the second most common cause of community acquired pneumonia. The purpose of this study was to demonstrate that, in a clinically relevant model, Bone Marrow MSCs attenuate multiple indices of the early acute phase of pneumonia, with enhanced effects after MSC priming. |
Methods: Rodents received an IT bolus of multi-drug resistant K.pneumoniae to induce pulmonary sepsis. BM-MSCs (naïve or primed) were given IV and 48h later animals were assessed for injury/repair. Blood gas analyses were carried out, and blood and bronchoalveolar lavage fluids were collected and analysed for cell numbers, phagocytic function, differential cell counts and CFU content while inflammatory cytokine content was quantified by ELISA.
Results: MSC administration resulted in the decrease in K.pneumoniae CFU, cell infiltrates and the proportion of inflammatory cells in the lung compared to control. BM-MSC therapy also resulted in an improvement in arterial oxygenation, and pulmonary and systemic inflammatory cytokine levels (Figure 1).
Conclusion: MSCs are effective in several models of pneumonia, including this clinically relevant K. pneumoniae model. Priming is a promising strategy to enhance their anti-inflammatory effects and resolution of injury in vivo.